Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A protein with new anticancer activity has been identified

2.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

5.

Use of marijuana and alcohol simultaneously is associated with worse outcomes.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot